Characterization of a protein product of human malignant glial tumors that induces microvascular permeability.
Criscuolo
G R
GR
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Merrill
M J
MJ
Oldfield
E H
EH
D000818:Animals; D001932:Brain Neoplasms / Q000032:analysis* / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects*; D003609:Dactinomycin / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects; D005910:Glioma / Q000032:analysis* / Q000473:pathology; D006632:Histamine / Q000494:pharmacology; D006633:Histamine Antagonists / Q000494:pharmacology; D006801:Humans; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000302:isolation & purification / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction; D014407:Tumor Cells, Cultured / Q000032:analysis; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D006633:Histamine Antagonists; D008222:Lymphokines; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003609:Dactinomycin; D003907:Dexamethasone; D006632:Histamine; D002118:Calcium